Introduction

Urology

Volumn 58, Issue 6, 2001, Pages 1-4

  Blute, Michael L ^a   Jacobsen, Steven J ^a   Kaplan, Steven A ^b   Lowe, Franklin C ^c   O’Leary, Michael P ^d   Steers, William D ^e   Roehrborn, Claus G ^f  

^a MAYO CLINIC   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC ALPHA ANTAGONISTS; ADRENERGIC BETA ANTAGONISTS; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE; TESTOSTERONE 5 ALPHA REDUCTASE;

ADULT; AGED; CONFERENCE PAPER; HUMAN; MALE; PHYTOTHERAPY; PROSTATE HYPERTROPHY;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; ENZYME INHIBITORS; HUMAN; MALE; MIDDLE AGE; PHYTOTHERAPY; PROSTATIC HYPERPLASIA; SUPPORT, NON-U.S. GOV'T; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0035651454     PISSN: None     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01536-9     Document Type: Editorial

References (13)

1. McConnell JD, Barry MJ, Bruskewitz RC, et al: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, Number 8. Rockville, MD, Agency for Health Care Policy and Research, US Public Health Service, US Dept of Health and Human Services, 1994. AHCPR Publication No. 94-0582.
2. C.G. Chute L.A. Panser C.J. Girman The prevalence of prostatism a population-based survey of urinary symptoms J Urol 150 1993 85 89
3. S.J. Jacobsen J.E. Oesterling M.M. Lieber Community-based population studies on the natural history of prostatism Curr Opin Urol 5 1995 13 17
4. J.L.H.R. Bosch W.C.J. Hop W.J. Kirkels The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume Br J Urol 75 1995 622 630
5. D.J.W. Hunter A. Berra-Unamuno A. Martin-Gordo Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older J Urol 155 1996 1965 1970
6. M.J. Barry F.J. Fowler Jr M.P. O’Leary The American Urological Association symptom index for benign prostatic hyperplasia J Urol 148 1992 1549 1557
7. H. Lepor The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia J Androl 12 1991 389 394
8. M. Carnie Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia Urol Clin North Am 17 1990 641 649
9. G. Bartsch R.S. Rittmaster H. Klocker Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia Eur Urol 37 2000 367 380
10. E. Stoner H. Guess Treatment of benign prostatic hyperplasia with 5 alpha-reductase inhibitors Endocrinologist 5 1995 140 146
11. M.L. Blute K.M. Tomera D.K. Hellerstein Transurethral microwave thermotherapy for management of benign prostatic hyperplasia results of the United States Prostatron Cooperative Study J Urol 150 1993 1591 1596
12. Denis L, McConnell JD, Yoshida O, et al: Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction, in Denis L, Griffiths K, Khoury S, et al (Eds): 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Plymouth, United Kingdom, Health Publication Ltd, 1997, pp 669–684.
13. J.A. Astin Why patients use alternative medicine result of a national study JAMA 279 1998 1548 1553